Wan Leader Intl (OTC:WANLF) Stock, Quote.Headers.trade-ideas

Wan Leader International Ltd is an investment holding company and the principal activities of its subsidiaries include the provision of freight forwarding and related logistics services and the provision of entrusted management services for operating an online e-commerce platform and Trading of fashion items. It generates maximum revenue from the Freight forwarding and related logistics services segment. Geographically, it generates the majority of its revenue from Hongkong.

WAN LEADER INTL LTD by WAN LEADER INTL LTD.

Wan Leader International Ltd

Trading Ideas

SFHG

Samfine Creation Holdings Group Shares Resumed Trade

APVO

Aptevo Therapeutics Shares Resumed Trade

Telehealth firm Ro has partnered with Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) to enhance patient access to Zepbound (tirzepatide) single-dose vials for obesity treatment.
Through LillyDirect, Ro will provide patients with streamlined access to this FDA-approved medication at a self-pay price, making it more affordable for clinically eligible individuals.
The collaboration <a target="_blank" href="https://www.prnewswire.com/news-releases/ro-works-with-lilly-to-streamline-patient-access-to-authentic-zepbound-single-dose-vials-by-integrating-with-lillys-pharmacy-channel-302328012.html" rel="noreferrer noopener">integrates</a> diagnosis, prescription, and home delivery into one platform.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42370795/investments-in-eli-lillys-production-capabilities-reaches-23-billion-with-additional-3-billion-expansion-at-us-facility" rel="noreferrer noopener">Eli Lilly Investments In Production Reach $23 Billion With Additional $3 Billion Expansion At US Facility</a>
Eli Lilly's executive vice president, Patrik Jonsson, emphasized the importance of affordability and accessibility in obesity care, noting that Zepbound's lower-cost vials represent a significant step toward breaking down barriers. "Our goal is to provide safe and effective treatment options that patients can trust," Jonsson stated.
"Lilly's release of Zepbound single-dose vials at a lower, self-pay-only price was groundbreaking and reflects the patient-centric model upon which Ro was founded. This integration further streamlines access to the only approved dual GIP and GLP-1 receptor agonist without patients ever having to leave the Ro app, let alone leave their home," said&nbsp;Zach Reitano, co-founder &amp; CEO of Ro.
CNBC <a target="_blank" href="https://www.cnbc.com/2024/12/11/ro-to-offer-weight-loss-drug-zepbound-vials-by-working-with-eli-lilly.html" rel="noreferrer noopener">notes</a> that the collaboration enables eligible patients to access Zepbound through a "complete end-to-end" experience. Patients can receive a diagnosis, obtain a prescription, and have the medication delivered directly to their homes via Gifthealth, a digital pharmacy partnered with LillyDirect.
Zepbound vials are cash-pay products priced at $399 for a 2.5 mg dose and $549 for a 5 mg dose.
Ro also provides extensive ongoing support for weight management, including personalized care plans, 24/7 access to licensed physicians, coaching, and tools for monitoring progress.
Using data, the <a target="_blank" href="https://ro.co/weight-loss/zepbound/#faq" rel="noreferrer noopener">platform </a>helps patients choose the most cost-effective medication, whether through insurance or cash payment.
Ro additionally assists with prescriptions for Novo Nordisk A/S' (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) rival drug, Wegovy (semaglutide), and compounded alternatives.
Last week, Eli Lilly revealed topline data from the SURMOUNT-5 phase 3b trial of Zepbound (tirzepatide) compared with Novo Nordisk's Wegovy (semaglutide) in adults with obesity, or overweight with at least one of the following comorbidities.
Zepbound provided a 47% greater relative weight loss compared to Wegovy. On average,&nbsp;Zepbound led to a superior weight loss of 20.2% compared to <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42316929/eli-lillys-zepbound-vs-novo-nordisks-wegovy-which-shows-greater-weight-loss" rel="noreferrer noopener">13.7% with Wegovy</a>.
Price Action: At last check Thursday, LLY stock was up 0.31% at $798.50.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42456428/kroger-and-albertsons-call-off-merger-plans-75-billion-share-buyback-cancels-47-billion-merger-debt" target="_blank" rel="noreferrer noopener">Kroger's $7.5 Billion Buyback Blitz: Eyes Lower Grocery Prices And Big Returns After Albertsons Pivot</a></li>
</ul>
Photo Source: Eli Lilly and Company

Biotech

Large Cap

News

Health Care

General

Telehealth Firm Ro Partners With Eli Lilly to Boost Access to Obesity Drug Zepbound

Rezolve AI Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLV#NASDAQ">RZLV</a>) shares are trading higher Thursday after the company announced plans to align with <a href="https://www.benzinga.com/pressreleases/24/12/g42458772/rezolve-ai-aligns-with-planned-department-of-government-efficiency-doge-initiatives-to-transform-r">Department of Government Efficiency (D.O.G.E.) initiatives</a>. 
What Happened: Rezolve AI announced its active participation in initiatives expected to align with the planned presidential advisory commission D.O.G.E.
The company said its BRAiNPOWA LLM and BRAiN Commerce platform are driving retail transformation through improved operational efficiency and noted that it believes its solutions are well-positioned to support the goals of D.O.G.E.
&#8220;Efficiency and innovation go hand in hand. By embracing the principles we expect the Department of Government Efficiency to champion, we are showcasing how artificial intelligence can revolutionize retail operations while empowering a leaner and more agile workforce,&#8221; said Daniel Wagner, CEO of Rezolve AI.
Key components of Rezolve AI&#8217;s &#8220;alignment&#8221; include streamlined operations, workforce optimization, innovative payment solutions, sustainability goals and enhanced accessibility.
See Also: <a href="https://www.benzinga.com/24/12/42453807/spacex-hits-350-billion-valuation-in-insider-share-sale-ceo-elon-musk-says-no-investors-wanted-to-sell-shares">SpaceX Hits $350 Billion Valuation In Insider Share Sale: CEO Elon Musk Says &#8216;No Investors Wanted To Sell Shares&#8217;</a>
<h3 class="wp-block-heading">How To Buy RZLV Stock</h3>
By now you're likely curious about how to participate in the market for Rezolve AI &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. In the case of Rezolve AI, which is trading at $1.99 as of publishing time, $100 would buy you 50.25 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
RZLV Price Action: <a href="http://benzinga.com/quote/rzlv">Rezolve AI shares</a> were up 9.55% at $2.18 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Movers

RZLV

What's Going On With Rezolve AI Stock Thursday?

Wells Fargo analyst Michael Brown upgrades Ares Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARES#NYSE">ARES</a>) from Equal-Weight to Overweight and raises the price target from $176 to $212.

Upgrades

Price Target

Analyst Ratings

ARES

Wells Fargo Upgrades Ares Management to Overweight, Raises Price Target to $212

ZenaTech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZENA#NASDAQ">ZENA</a>) shares are trading higher in the <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">premarket session on Thursday.</a>
The Toronto-based company launched Sky Traffic, leveraging quantum computing through Amazon Web Services (AWS) and drones to monitor traffic. The drones will offer real-time data to government agencies as well as drivers.
The goal is to improve traffic flow, routing, signal management, public safety, and government services by processing large datasets.
Also Read: <a href="https://www.benzinga.com/24/12/42456905/us-stocks-to-open-lower-despite-strong-probability-of-upcoming-fed-rate-cut-market-breadth-skewed-in-the-favor-of-bears-over-the-last-seven-session" target="_blank" rel="noreferrer noopener">Wall Street Poised To Open Lower A Day After Nasdaq&#8217;s Record Close Above 20,000</a>
Sky Traffic was developed after ZenaTech received interest from a government client, eager to enhance traffic monitoring with cutting-edge technology.
The project will accelerate data processing, enabling better decision-making and automation in real time. ZenaTech also plans to integrate its drones into weather radar applications, enhancing the precision of weather forecasting, especially in predicting extreme weather events.
&#8220;Integrating quantum computing with AI-driven drones will revolutionize how we analyze and respond to complex data, enabling faster, more accurate decision-making and unlocking new possibilities in automation, efficiency, and real-time problem-solving,&#8221; CEO Shaun Passley said.
Meanwhile, quantum stocks have rallied in recent weeks as excitement around the <a target="_blank" href="https://www.benzinga.com/24/12/42443727/whats-going-on-with-rigetti-computing-stock-wednesday" rel="noreferrer noopener">potential of quantum computing builds.</a>
On Tuesday, Google unveiled a new quantum computing chip called &#8220;Willow,&#8221; marking a 30-year breakthrough in quantum error correction.
Google said in a blog post that the quantum chip performed a standard benchmark computation in under five minutes. That same computation would take one of today's&nbsp;fastest supercomputers&nbsp;<a target="_blank" href="https://www.benzinga.com/24/12/42447332/alphabets-quantum-willow-chip-wows-analyst-google-at-the-leading-edge-of-technology-innovation" rel="noreferrer noopener">10 septillion years to complete.</a>
Quantum computers are expected to be able to process much bigger volumes of data than traditional computers by using qubits instead of bits, which are limited to ones and zeroes. Being able to process higher volumes of data could potentially lead to more breakthroughs in critical research areas, which has sparked excitement about the potential of quantum companies.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42453807/spacex-hits-350-billion-valuation-in-insider-share-sale-ceo-elon-musk-says-no-investors-wanted-to-sell-shares" target="_blank" rel="noreferrer noopener">SpaceX Hits $350 Billion Valuation In Insider Share Sale: CEO Elon Musk Says ‘No Investors Wanted To Sell Shares'</a></li>
</ul>
Image: Shutterstock

Markets

Tech

ZENA

Quantum Computing Meets Drones: ZenaTech Launches Sky Traffic Project For Traffic, Weather Optimization

Samfine Creation Holdings Group Shares Halted On Circuit Breaker To The Downside, Stock Now Down -48.2%

JMP Securities analyst Andrew Boone reiterates Shopify (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) with a Market Outperform and maintains $120 price target.

Reiteration

SHOP

JMP Securities Reiterates Market Outperform on Shopify, Maintains $120 Price Target

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Seaport Global analyst David Joyce upgraded the rating for Comcast Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) from Neutral to Buy and announced a $46 price target. Comcast shares closed at $39.71 on Wednesday. <a href="https://www.benzinga.com/quote/CMCSA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wolfe Research analyst Nigel Coe upgraded Parker-Hannifin Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PH#NYSE">PH</a>) from Peer Perform to Outperform. Parker Hannifin shares closed at $686.39 on Wednesday. <a href="https://www.benzinga.com/quote/PH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Noah Poponak upgraded the rating for Parsons Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSN#NYSE">PSN</a>) from Neutral to Buy and raised the price target from $103 to $111. Parsons shares closed at $95.19 on Wednesday. <a href="https://www.benzinga.com/quote/PSN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Deutsche Bank analyst Steve Powers upgraded The Coca-Cola Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) from Hold to Buy and raises the price target from $68 to $70. Coca-Cola shares closed at $62.64 on Wednesday. <a href="https://www.benzinga.com/quote/KO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc analyst Brandon Nispel upgraded the rating for Charter Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) from Sector Weight to Overweight and maintained the price target of $500. Charter Communications shares closed at $378.49 on Wednesday. <a href="https://www.benzinga.com/quote/CHTR/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying KO stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="575" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12093427/image-102-1024x575.png" alt="" class="wp-image-689592" style="width:562px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12093427/image-102-1024x575.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12093427/image-102-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12093427/image-102-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12093427/image-102.png 1123w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42437595/jim-cramer-says-keep-owning-this-energy-stock-abbott-laboratories-legal-stuff-is-behind-them">Jim Cramer Says &#8216;Keep Owning&#8217; This Energy Stock, Abbott Laboratories &#8216;Legal Stuff&#8217; Is Behind Them</a></li>
</ul>

CHTR

CMCSA

This Coca-Cola Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Oppenheimer analyst Tyler Batory maintains Toll Brothers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>) with a Outperform and maintains $189 price target.

Oppenheimer Maintains Outperform on Toll Brothers, Maintains $189 Price Target

SEER commits to an aggressive decarbonization and carbon credit monetization program, starting with its current MV Technology solutions and its planned biocarbon production facilities both domestic and international.
BROOMFIELD, CO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=wWeNjwuKVscfBb8iSWOS6KOuFfYlgP58VnQyWCNR511nEpHCQXzFlBti48KxNYSVU_evWbbJWyjcNCbVKaWi76UC1ezMdpTe9bAzxBsyaEk38VpWN34Vpu2tD40OrWRZECsBkx6x6YMuAHU6Rih8Ng==">Strategic Environmental &amp; Energy Resources, Inc.</a>&nbsp;(SEER) (OTCQB:&nbsp;<a href="https://www.globenewswire.com/Tracker?data=otIrNvpDfGrtGkckwPgtulP1h5Fz0sWWOuac9wpq5raSQzkxrQQalVKqTw-qetqs86YhbAiBrzg0dDyVvjXZtRZB_yPQWnuiK9r6Bo_EyDY=">SENR</a>), a provider of environmental, renewable fuels and industrial waste stream management services, has partnered with DevvStream, Inc., an emerging leader in carbon credit investing and monetization (<a href="https://www.globenewswire.com/Tracker?data=1UAN8Rn2W5rFehi5-1tNUr1BQhVfp5JR27cqT9D7bburUsOAG-Ter-HdbRJastHpys4HEBbNSCJyeA5ocxZjOx7jK8LpYWcSVM2UOL77MrQ=">https://www.devvstream.com/</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DEVS#NASDAQ">DEVS</a>). Together, SEER and DevvStream, intend to develop a comprehensive program to quantify and monetize high-quality carbon credits arising out of 1) biogas capture and conditioning associated with generating methane renewable energy, 2) the prevention of harmful fugitive emissions from small, vertical oil &amp; gas wells, and 3) the sequestration of CO2 at SEER&#39;s planned &quot;biocarbon&quot; production facilities in Texas and Saudi Arabia.

Global

DEVS

SEER Partners With Devvstream To Monetize Insured Carbon Credits Arising Out Of Biogas Capture And Conditioning Associated With Generating Methane Renewable Energy, The Prevention Of Harmful Fugitive Emissions From Small, Vertical Oil & Gas Wells, And The Sequestration Of CO2 At SEER's Planned "Biocarbon" Production Facilities In Texas And Saudi Arabia

Aptevo Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 39%

Wells Fargo analyst Zachary Fadem upgrades Brinker International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>) from Underweight to Equal-Weight and raises the price target from $95 to $130.

Wells Fargo Upgrades Brinker International to Equal-Weight, Raises Price Target to $130

Oppenheimer analyst Chris Kotowski maintains StepStone Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STEP#NASDAQ">STEP</a>) with a Outperform and raises the price target from $73 to $84.

STEP

Oppenheimer Maintains Outperform on StepStone Group, Raises Price Target to $84

Journal is the official publication of the International Union of Immunological Societies
Marlborough, Massachusetts--(Newsfile Corp. - December 12, 2024) - Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL&#xAE; siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells announced today its manuscript, Self-delivering RNAi Immunotherapeutic PH-762 Silences PD-1 to Generate Local and Abscopal Anti-tumor Efficacy, has been published in the December, 2024 issue of Frontiers in Immunology.
The article presents preclinical proof-of-concept data for PH-762, an INTASYL compound designed to silence PD-1, is currently in clinical development for advanced cutaneous malignancies. Phio recently presented data from its second cohort in its on-going Phase 1b clinical trial showing one patient with cutaneous squamous cell carcinoma in the 2nd cohort achieved a complete response (100% tumor clearance) while a second patient with squamous cell carcinoma achieved a partial response (90% tumor clearance).

PHIO

Phio Pharmaceuticals Announces Publication In Frontiers In Immunology Announces Its Manuscript, Self-Delivering RNAi Immunotherapeutic PH-762 Silences PD-1 To Generate Local And Abscopal Anti-Tumor Efficacy, Has Been Published In The December, 2024 Issue Of Frontiers In Immunology

Oppenheimer analyst Chris Kotowski maintains P10 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>) with a Outperform and raises the price target from $17 to $21.

Oppenheimer Maintains Outperform on P10, Raises Price Target to $21

Oppenheimer analyst Chris Kotowski maintains KKR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) with a Outperform and raises the price target from $153 to $175.

Oppenheimer Maintains Outperform on KKR, Raises Price Target to $175

MULN

Mullen Subsidiary, Bollinger Motors, Delivered First 25 B4 Trucks, With Retail Sales Of ~$4.1M Nearly Three Months Since Start Of Production In Sept.

Oppenheimer analyst Chris Kotowski maintains GCM Grosvenor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCMG#NASDAQ">GCMG</a>) with a Outperform and raises the price target from $18 to $20.

GCMG

Oppenheimer Maintains Outperform on GCM Grosvenor, Raises Price Target to $20

Leerink Partners analyst Daina Graybosch downgrades LAVA Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVTX#NASDAQ">LVTX</a>) from Outperform to Market Perform and lowers the price target from $11 to $2.

Comments

Wan Leader Intl

Wan Leader Intl (WANLF) Forecast

Wan Leader Intl (OTC:WANLF) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga